Spire Wealth Management Increases Holdings in Moderna, Inc. (NASDAQ:MRNA)

Spire Wealth Management boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 17.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,308 shares of the company’s stock after purchasing an additional 197 shares during the period. Spire Wealth Management’s holdings in Moderna were worth $139,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Ogorek Anthony Joseph NY ADV purchased a new position in Moderna during the 4th quarter valued at about $27,000. Arlington Trust Co LLC grew its holdings in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after acquiring an additional 290 shares during the period. Westside Investment Management Inc. purchased a new position in shares of Moderna during the 1st quarter worth approximately $32,000. Rise Advisors LLC grew its holdings in shares of Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after acquiring an additional 286 shares during the period. Finally, Byrne Asset Management LLC purchased a new position in shares of Moderna during the 1st quarter worth approximately $45,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Activity

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $127.32, for a total value of $1,909,800.00. Following the completion of the sale, the director now directly owns 1,996,931 shares in the company, valued at approximately $254,249,254.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $127.32, for a total value of $1,909,800.00. Following the completion of the sale, the director now directly owns 1,996,931 shares in the company, valued at approximately $254,249,254.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Stephen Hoge sold 255 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The disclosure for this sale can be found here. Insiders have sold 170,209 shares of company stock valued at $18,588,421 in the last ninety days. 15.20% of the stock is currently owned by company insiders.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $8.11 during midday trading on Monday, hitting $141.01. 4,707,152 shares of the stock traded hands, compared to its average volume of 4,067,296. The firm has a 50-day moving average of $110.78 and a two-hundred day moving average of $97.87. The firm has a market capitalization of $54.04 billion, a P/E ratio of -9.00 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. Moderna, Inc. has a one year low of $62.55 and a one year high of $142.79.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company’s revenue was down 91.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.19 EPS. On average, equities analysts forecast that Moderna, Inc. will post -7.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. HSBC reiterated a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. UBS Group upped their target price on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Royal Bank of Canada upped their target price on Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Finally, Evercore ISI assumed coverage on Moderna in a research report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $126.46.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.